Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07127705 · ClinicalTrials.gov registry record · NA
Rapid Response of Stem Cells and Immune Cells for Efficacy
A NA study of Stem Cell Surveillance, sponsored by Natural Immune Systems.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07127705: Recruiting NA study of Stem Cell Surveillance, sponsored by Natural Immune Systems.
NCT07127705 is a NA study of Stem Cell Surveillance that is actively recruiting participants, run by Natural Immune Systems. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07127705, a NA study of Stem Cell Surveillance, is actively recruiting participants, sponsored by Natural Immune Systems.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal for this clinical trial is to compare rapid effects of four products on stem cells, immune activation, and mitochondrial function. A double-blind, placebo-controlled, cross-over study design will be used.
Primary Outcome
Changes to the number of stem cells in the blood circulation (number of cells per mL blood). Data is collected on the following types of stem cells: CD45dimCD34+CD309+, CD45dimCD34+CD309-, CD31++CD34-, CD45-CD90+.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Chaga Mushroom
- DIETARY_SUPPLEMENT Ginseng extract
- DIETARY_SUPPLEMENT Olive extract
- DIETARY_SUPPLEMENT Potassium Hydrogen Glucarate
Study Locations (1)
Oregon
- NIS Labs - Klamath Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2025-10-03 |
| Phase | NA |
What NCT07127705 shows while recruiting
NCT07127705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Stem Cell Surveillance appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT07127705 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT07127705 about?
NCT07127705 is a clinical study titled "Rapid Response of Stem Cells and Immune Cells for Efficacy". The goal for this clinical trial is to compare rapid effects of four products on stem cells, immune activation, and mitochondrial function. A double-blind, placebo-controlled, cross-over study design will be used.
What is the current status of trial NCT07127705?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-05-21. Estimated completion is 2025-10-03.
What conditions does trial NCT07127705 study?
This clinical trial studies the following conditions: Stem Cell Surveillance.
What interventions are being tested in trial NCT07127705?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Chaga Mushroom (DIETARY_SUPPLEMENT), Ginseng extract (DIETARY_SUPPLEMENT), Olive extract (DIETARY_SUPPLEMENT), Potassium Hydrogen Glucarate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07127705?
This trial is sponsored by Natural Immune Systems, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07127705 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07127705's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI